Zai Lab Limited (ZLAB) Fair Value 2026

ZLAB · Pharmaceutical Preparations ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-07-15, Zai Lab Limited (ZLAB) trades at $20.44, approximately 160% above CirclFi’s Bayesian DCF fair value of $7.87. QOC: 4.2/10. Value Trap Risk: 30/100 (LOW). 11/13 models active.

Key Facts

Ticker
ZLAB
Price
$20.44
Quality Score
4.2/10
Value Trap Risk
30/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +44.7% upside with 15% confidence
Risk: Below-average Quality Score of 4.2/10 signals weak fundamentals

Is Zai Lab Limited (ZLAB) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Zai Lab Limited (ZLAB) appears overvalued as of : the median of 11 independent fair value estimates is $9.46, 53.7% below the current price of $20.44. Estimates range from $1.57 to $29.57. ZLAB scores 4.2/10 on fundamental quality and 30/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Zai Lab Limited Stock in 2026? →

Valuation Matrix

11 Intrinsic Value Models vs. Current Price ($20.44)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$7.87 -61.5%
Earnings Power Value
High Conviction
$9.46 -53.7%
CUCE Ensemble
Low Conviction
$10.70 -47.6%
First Chicago
Low Conviction
$29.57 +44.7%

Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is Zai Lab Limited (ZLAB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Zai Lab Limited's intrinsic value is estimated at $12.28, suggesting the stock is overvalued at its current price of $20.44. With 9 out of 11 models flagging downside (-39.9% average return), the market may be pricing in unsustainable growth. The most optimistic model, First Chicago, places fair value at $29.57 (+44.7%), while ML-RIV — the most conservative — estimates $1.57 (-92.3%). This +137.0% gap reflects genuine analytical uncertainty about Zai Lab Limited's intrinsic worth.

What Do the Models Say About ZLAB?

11 of 13 models are currently active for ZLAB. Of these, 2 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates ZLAB's intrinsic value at $7.87, implying -61.5% downside from the current price. See which stocks rank higher →

How Does ZLAB Rank in Pharmaceutical Preparations?

Among 431 Pharmaceutical Preparations stocks, ZLAB ranks #309 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Pharmaceutical Preparations Stocks →

As a pharmaceutical industry, Zai Lab Limited operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating ZLAB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ZLAB a Value Trap?

CirclFi's Value Trap algorithm assigns ZLAB a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Zai Lab Limited. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Zai Lab Limited's fundamental quality profile registers 4.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +137.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZLAB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ZLAB's 11 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Zai Lab Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Pharmaceutical Preparations Stocks Should You Also Analyze?

8 related Pharmaceutical Preparations stocks with 13-model coverage

Read investment analysis: AZN · CPRX · HRMY · NVO · SIGA

See all Pharmaceutical Preparations stocks ranked →

Frequently Asked Questions About Zai Lab Limited

What is Zai Lab Limited's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Zai Lab Limited (ZLAB) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $7.87. The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZLAB overvalued or undervalued right now?

At $20.44, 2 of 11 active models suggest ZLAB may be undervalued, while 9 indicate potential overvaluation. The median of all 11 fair value estimates is $9.46, 53.7% below the current price of $20.44 — a consensus view that ZLAB is overvalued. The assessment depends on which methodology best fits Zai Lab Limited's business model in Pharmaceutical Preparations.

What does a Quality of Company score of 4.2 mean for ZLAB?

Zai Lab Limited's QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ZLAB?

CirclFi analyzes ZLAB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Is ZLAB a value trap in 2026?

Zai Lab Limited's Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Zai Lab Limited (ZLAB) has a median fair value of $9.46 — 53.7% below the current price of $20.44 — as of 2026-07-15.” Source: circlfi.com/stock/ZLAB/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on ZLAB.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access